HuZAF

(Fontolizumab)
By
GROUP 4
1. WULANDARI
(1310411095)
2. RAHMADINI ANWAR
(1310412006)
3. RIANGGA BAYU HANAFI (1310412052)

FACULTY OF MATHEMATHICS AND NATURAL SCIENCE

ANDALAS UNIVERSITY

NOMENCLATURE OF THE
BIOLOGICAL AGENTS
"-cept" refers to fusion of a
receptor to the Fc part of human
IgG1
"-mab" indicates a monoclonal
antibody (mAb)
"-ximab" indicates a chimeric mAb

"-zumab" or "-mumab" indicates

a humanized mAb

PRODUCER

PDLS DEVELOPMENT
PORTFOLIO

HuZAF (FONTOLIZUMAB)
Huzaf are monoclonal antibody &
anti-interferon-g antibody
Clinical trial in 133 patients with
moderate or severe Crohn's disease
show
clinical
improvement
receiving 4 or 10 mg/kg
~1/2 patients in remission by
day 45
Post-hoc analysis suggested
response most significant with
Well tolerated.
CRP > 10Additional studies are

ONGOING

HuZAF (FONTOLIZUMAB)
Immunohistochemistry
analysis of CD3, Stat1,
CXCR3, Ki67, and HLADR
from
mucosal
biopsy predosing and
at day 29 after a single
dose of 4 mg/kg
fontolizumab in a
single patient with
Crohn disease.
CD3[A,F], Stat1[B,G],
CXCR3[C,H], Ki67 [D,I],
and HLA-DR[#,J. [A-E]
Baseline; [F-J] day 29

FUNDAMENTAL SEQUENCE OF
PROINFLAMMATORY CYTOKINES
ACTION ON TISSUE

THERAPY OF HuZAF
Recent studies have examined
the safety and efficacy of HuZAF
in the treatment of moderate to
severe Crohns disease (CD). CD
is a chronic inflammatory
disease of the gastrointestinal
tract. IFN-
has been
implicated in the inflammation
observed in CD and increased
levels are found in the mucosa.

THANKS
FACULTY OF MATHEMATHICS AND NATURAL SCIENCE
ANDALAS UNIVERSITY